Table 1.

Age (in Years) and Risk-Specific Disease Rate, Vaccine Effectiveness, Coverage Rate, and Cost Inputs for Prediction Model

Disease
	Age 50–64, Healthy		Age 50–64, High-risk		Age ≥ 65, Healthy		Age ≥ 65, High-risk
	base	range	base	range	base	range	base	range
IPD rate (per 100,000)a	8.62	6.5–8.94	33.71	32.33–34.6	15.06	13.25–16.04	47.63	47.63–62.82
% IPD cases resulting in fatality	6.74		11.62		11.85		15.05
% PCV13 serotype IPD	26.75		24.8		24.7		21.32
% PPSV23 serotype IPD	74.52		69.19		62.35		59.69
% PPSV23 serotype IPD (but not in PCV13)	48.09		44.39		38.06		38.37
% Nonvaccine Serotype IPD	25.16		30.81		37.25		40.31
Inpatient NBP rate (per 100,000)b	258.2	258.2–267.7	258.2	258.2–267.7	1375.2	1375.2–1438.4	1375.2	1375.2–1438.4
% NBP cases resulting in fatalityc	3.2	2–4	3.2	2–4	6.7	5–7	6.7	5–7
Outpatient NBP rate (per 100,000)d	600		600		2010		2010
% NBP due to PCV13 typese	10	9–14	10	9–14	10	9–14	10	9–14
Serotype changes between 2003 and 2009a
(cases per 100,000)	Age 50–64, Healthy		Age 50–64, High-risk		Age ≥ 65, Healthy		Age ≥ 65, High-risk
Year	2003	2009	2003	2009	2003	2009	2003	2009
PCV7 types	6.26	1.34	6.26	1.34	13.62	1.82	13.62	1.82
PPSV23 types not in PCV7	8.35	14.85	8.35	14.85	20.83	24.38	20.83	24.38
Types in neither PCV7 nor PPSV23	3.61	5.01	3.61	5.01	7.67	12.62	7.67	12.62
Vaccine effectiveness
	Age 50–64, Healthy		Age 50–64, High-risk		Age ≥ 65, Healthy		Age ≥ 65, High-risk
	base	range	base	range	base	range	base	range
PCV vs. VT IPDe	75.00	41.43–90.78	75.00	41.43–90.78	75.00	41.43–90.78	75.00	41.43–90.78
PCV vs. VT NBPe	45.00	14.21–65.31	45.00	14.21–65.31	45.00	14.21–65.31	45.00	14.21–65.31
PPSV vs. VT IPDf	74.00	64–85	74.00	48–85	74.00	64–85	74.00	64–85
PPSV vs. VT NBPg	0	0–50	0	0–50	0	0–50	0	0–50
Vaccine coverage
	Age 50–64, Healthy		Age 50–64, High-risk		Age ≥ 65, Healthy		Age ≥ 65, High-risk
	base	range	base	range	base	range	base	range
Coverage rate (%)h	27.2	20–54.4	20	18.9–21.1	59.9	58.4–61.4	59.9	58.4–61.4
Cost per case, 2010$j
	Age 50–64, Healthy		Age 50–64, High-risk		Age ≥ 65, Healthy		Age ≥ 65, High-risk
	base	range	base	range	base	range	base	range
IPD	40,161	31,950–49,086	40,161	31,950–49,086	27,097	21,981–32,695	27,097	21,981–32,695
Inpatient NBP	34,948	25,468–46,117	34,948	25,468–46,117	23,296	16,916–31,696	23,296	16,916–31,696
Outpatient NBP	127	77–219	127	77–219	254	121–463	254	121–463

Abbreviations: IPD invasive pneumococcal disease, PCV13 13-valent pneumococcal conjugate vaccine, PPSV23 23-valent pneumococcal polysaccharide vaccine, NBP non-bacteremic pneumococcal pneumonia, VT vaccine type

^a Source: ABCs surveillance data 2013.¹¹ Note inputs from ABCs are displayed here for reproducibility of final results. The number of digits displayed should not necessarily be construed as a measure of the accuracy of these outputs from ABCs surveillance data

^b Source: Simonsen et al. 2014³

^c Source: Huang et al. 2011¹³

^d Source: Nelson et al. 2008¹²

^e Source: CAPITA

^f Source: Moberley et al. 2008¹⁴

^g Source: Huss et al. 2009¹⁵

^h Source: National Health Interview Survey 2012^{16 , 17}

^j Source: MarketScan 2010¹⁸